参考文献/References:
[1]Higashiyama M,Tomita K,Sugihara N,et al.Chitinase 3-like 1 deficiency ameliorates liver fibrosis by promoting hepatic macrophage apoptosis[J].Hepatology Research,2019,49(11):1316-1328.[2]Kzhyshkowska J,Mamidi S,Gratchev A,et al.Novel stabilin-1 interacting chitinase-like protein(SI-CLP)is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway[J].Blood,2006,107(8):3221-3228.[3]Qiu QC,Wang L,Jin SS,et al.CHI3L1 promotes tumor progression by activating TGF-β signaling pathway in hepatocellular carcinoma[J].Sci Rep,2018,8(1):15029.[4]Vaananen T,Vuolteenaho K,Kautiainen H,et al.NEO-RACo Study Group. Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial[J].PLoS One,2017,12(8):e0183294.[5]Jiang Z,Wang S,Jin J,et al.The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases[J].J Clin Lab Anal,2020,34(5):e23200.[6]Kang Q,Chen J,Luo H,et al.Decrease in Chitinase 3-Like Protein 1 Levels Reflects Improvement in Liver Fibrosis after HCV Eradication[J].Dis Markers,2020(2020):8539804.[7]Huang H,Wu T,Mao J,et al.CHI3L1 Is a Liver-Enriched, Noninvasive Biomarker That Can Be Used to Stage and Diagnose Substantial Hepatic Fibrosis[J].OMICS,2015,19(6):339-345.[8]Roslind A,Johansen JS.YKL-40:a novel marker shared by chronic inflammation and oncogenic transformation[J].Methods Mol Biol,2009(511):159-184.[9]Kumagai E,Mano Y,Yoshio S,et al.Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease[J].Sci Rep,2016(6):35282.[10]Johansen JS.Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling,fibroses and cancer[J].Dan Med Bull,2006(53):172-209.[11]李祥波.几丁质酶样3蛋白1及基质金属蛋白酶-9在人颈动脉粥样硬化斑块中表达的相关研究[D].郑州大学,2016.[12]Yang M,Jiang L,Wang Y,et al.Step layered combination of noninvasive fibrosis models improves diagnostic accuracy of advanced fibrosis in nonalcoholic fatty liver disease[J].J Gastrointestin Liver Dis,2019,28(3):289-296.[13]朱萍,路毓峰,王丽,等.慢性乙型肝炎患者肝纤维化血清标志物与肝组织炎症分级的关系[J].河北医药,2019,41(16):2497-2500.[14]Oslobanu A,Florian SI.Is YKL-40 (CHI3-L1) a new possible biomarker prognosticator in high grade glioma?[J].Romanian Neurosurgery,2015,29(3):247-253.[15]Wurm J,Behringer SP,Ravi VM,et al.Astrogliosis Releases Pro-Oncogenic Chitinase 3-Like 1 Causing MAPK Signaling in Glioblastoma[J].Cancers(Basel),2019,11(10):1437.[16]Lee CM,He CH,Nour AM,et al.IL-13Rα2 uses TMEM219 in chitinase 3-like-1-induced signalling and effector responses[J].Nat Commun,2016(7):12752.[17]Coffman FD.Chitinase 3-Like-1(CHI3L1):a putative disease marker at the interface of proteomics and glycomics[J].Crit Rev Clin Lab Sci,2008,45(6):531-562.[18]Yan L,Deng Y,Zhou J,et al.Serum CHI3L1 as a biomarker for liver fibrosis in chronic hepatitis B patients with normal and mildly elevated ALT[J].Infection,2018,46(3):385-393.[19]Wang L,Liu T,Zhou J,et al.Changes in serum chitinase 3-like 1 levels correlate with changes in liver fibrosis measured by two established quantitative methods in chronic hepatitis B patients following antiviral therapy[J].Hepatol Res,2018,48(3):E283-E290.[20]Jin X,Fu B,Wu ZJ,et al.Serum chitinase-3-like protein 1 is a biomarker of liver fibrosis in patients with chronic hepatitis B in China[J].Hepatobiliary Pancreat Dis Int,2020,19(4):384-389.[21]Jiang Z,Wang S,Jin J,et al.The clinical significance of serum chitinase 3-like 1 in hepatitis B-related chronic liver diseases[J].J Clin Lab Anal,2020,34(5):e23200.[22]Rath T,Roderfeld M,Güler C,et al.CHI3L1 and transient elastography,a powerful team to assess hepatic fibrosis.Scand J Gastroenterol[J].Scand J Gastroenterol,2011,46(11):1369-1380.[23]Orasan OH,Ciulei G,Cozma A,et al.Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies[J].Clujul Med,2016,89(1):24-31.[24]Mushtaq S,Ghani E,Azam K,et al.Comparison of chitinase-3-like protein 1,aspartate aminotransferase-to-platelet ratio index,and fibrosis-4 index with shear-wave elastography[J].Eur J Gastroenterol Hepatol,2019,31(3):357-362.[25]Mehta P,Ploutz-Snyder R,Nandi J,et al.Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II,and CHI3L1 for discriminating fibrosis stages in chronic hepatitis C[J].Am J Gastroenterol,2008,103(4):928-936.[26]Lebensztejn DM,Wierzbicka A,Socha P,et al.Cytokeratin-18 and hyaluronic acid levels predict liver fibrosis in children with non-alcoholic fatty liver disease[J].Acta Biochimica Polonica,2011,58(4):563-566.[27]Lee CK,Perez-Atayde AR,Mitchell PD,et al.Serum biomarkers and transient elastography as predictors of advanced liver fibrosis in a United States cohort:the Boston children’s hospital experience[J].J Pediatr,2013,163(4):1058-1064.[28]毛玉环,谭黎明,李建英,等.血清壳多糖酶3样蛋白1和甲胎蛋白及铁蛋白检测在原发性肝癌诊断中的应用评价[J].实用预防医学,2018,25(4):401-404.[29]曾光群,魏世刚,杨成,等.血清壳多糖酶3样蛋白1和甲胎蛋白联合检测对不同肝脏疾病的诊断价值[J].实用医院临床杂志,2019,16(5):83-86.[30]Pan JJ,Ge YS,Xu GL,et al.The expression of chitinase 3-like 1:anovel prognostic predictor for hepatocellular carcinoma J Cancer[J].Res Clin Oncol,2013,139(6):1043-1054.
相似文献/References:
[1]王艳欣,孟庆华,朱跃科.非侵入性检查方法评价肝纤维化的研究进展[J].医学信息,2018,31(03):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
WANG Yan-xin,MENG Qing-hua,ZHU Yue-ke.Progress in Evaluation of Liver Fibrosis by Non-invasive Methods[J].Medical Information,2018,31(10):40.[doi:10.3969/j.issn.1006-1959.2018.03.014]
[2]李顶春,李 武.Wnt信号通路与肝纤维化[J].医学信息,2018,31(09):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
LI Ding-chun,LI Wu.Wnt Signaling Pathway and Hepatic Fibrosis[J].Medical Information,2018,31(10):4.[doi:10.3969/j.issn.1006-1959.2018.09.002]
[3]艾迎春,迟男男,杜景峰,等.芪参二莲汤对肝纤维化大鼠基质金属蛋白酶-1及
抑制因子的影响[J].医学信息,2018,31(15):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
AI Ying-chun,CHI Nan-nan,DU Jing-feng,et al.Effects of Qishenerlian Decoction on Matrix Metalloproteinase-1 and Its Inhibitory Factors in Rats with Hepatic Fibrosis[J].Medical Information,2018,31(10):140.[doi:10.3969/j.issn.1006-1959.2018.15.045]
[4]董 朴,蔡福景,张 东,等.胆维他片对肝纤维化大鼠肝中抗氧化体系的影响[J].医学信息,2019,32(18):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
DONG Pu,CAI Fu-jing,ZHANG Dong,et al.Effect of Danweiita Tablet on Antioxidant System in Liver of Rats with Hepatic Fibrosis[J].Medical Information,2019,32(10):138.[doi:10.3969/j.issn.1006-1959.2019.18.046]
[5]皮青文.恩替卡韦抗病毒治疗对慢性乙肝肝硬化患者肝功能及肝硬化程度的影响[J].医学信息,2022,35(15):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
PI Qing-wen.Effect of Entecavir Antiviral Therapy on Liver Function and Degree of Liver Cirrhosis in Patients with Chronic Hepatitis B Cirrhosis[J].Medical Information,2022,35(10):121.[doi:10.3969/j.issn.1006-1959.2022.15.028]
[6]林思萍,龚先琼.中药单体调控TGF-β1/Smads信号通路抗纤维化的研究[J].医学信息,2019,32(21):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
LIN Si-ping,GONG Xian-qiong.Study on Anti-Fibrosis of TGF-β1/Smads Signaling Pathway Regulated by Chinese Medicine Monomer[J].Medical Information,2019,32(10):30.[doi:10.3969/j.issn.1006-1959.2019.21.011]
[7]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Medical Information,2020,33(10):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
[8]邹克平.超声实时剪切波弹性成像对血吸虫病肝纤维化的诊断效能分析[J].医学信息,2022,35(18):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
ZOU Ke-ping.Analysis of Diagnostic Efficacy of Ultrasound Shear Wave Elastography in Schistosomiasis Liver Fibrosis[J].Medical Information,2022,35(10):150.[doi:10.3969/j.issn.1006-1959.2022.18.042]
[9]郭 冶,卢凤美,刘东璞.肝纤维化发病机制及大黄酸对肝纤维化的作用[J].医学信息,2020,33(12):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
GUO Ye,LU Feng-mei,LIU Dong-pu.The Pathogenesis of Hepatic Fibrosis and the Effect of Rhein on Hepatic Fibrosis[J].Medical Information,2020,33(10):27.[doi:10.3969/j.issn.1006-1959.2020.12.010]
[10]徐勇平.舒肝宁注射液治疗晚期血吸虫病肝纤维化的效果及其对血清指标的影响[J].医学信息,2020,33(24):151.[doi:10.3969/j.issn.1006-1959.2020.24.043]
XU Yong-ping.Shuganning Injection in the Treatment of Advanced Schistosomiasis Liver Fibrosis and Its Influence on Serum Indexes[J].Medical Information,2020,33(10):151.[doi:10.3969/j.issn.1006-1959.2020.24.043]